Pharmaceutical Technology

APRIL 4, 2023

On April 3, Janssen Pharmaceutical Companies of Johnson & Johnson announced the availability of an additional 240mg strength tablet for its prostate cancer drug ERLEADA (apalutamide) in the United States. Previously, the drug was only available as a 60mg tablet – four of the which would need to be daily. billion in 2021.

Food and Drug Administration 98

Food and Drug Administration Food Medical Patients 98

European Pharmaceutical Review

JUNE 29, 2023

The world’s first AI-generated anti-fibrotic small molecule inhibitor drug has been administered to the first human patients. Phase II clinical trials in the US and China are now underway for INS018_055, Insilico Medicine’s potentially first-in-class oral drug candidate. Patients will be divided into four parallel cohorts.

Food and Drug Administration 98

Food and Drug Administration Safety Recruitment FDA 98

European Pharmaceutical Review

NOVEMBER 16, 2022

The drug will support patients in the worsening opioid crisis in the US, driven by the increased prevalence of synthetic opioids, such as fentanyl. Other drugs in Opiant’s development pipeline include OPNT004, a CB-1 antagonist in preclinical development as a potential injectable treatment for acute cannabinoid overdose (ACO).

Food and Drug Administration 98

Food and Drug Administration Pharma Pharmaceutical Food 98

MedCity News

JUNE 12, 2023

Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence. million increase over 2021. Nearly 20% of U.S.

Food and Drug Administration 261

Food and Drug Administration Prescription Government FDA 261

European Pharmaceutical Review

JANUARY 16, 2023

The US Food and Drug Administration (FDA) has approved Rykindo ® (risperidone) for extended-release injectable suspension. The drug is indicated as a bi-weekly treatment for schizophrenia and as monotherapy or as adjunctive therapy to lithium or valproate for bipolar I disorder in adults.

Food and Drug Administration 122

Food and Drug Administration FDA Competition Pharma 122

European Pharmaceutical Review

DECEMBER 21, 2022

Most psychedelic drugs are Schedule I controlled substances, which means that very strict legal and regulatory controls accompany their use” Some psychedelics originate in nature and have been used by Indigenous cultures for thousands of years; others are manipulated or manufactured. 1 Such restraints have stood solid for decades. .

Food and Drug Administration 119

Food and Drug Administration Medicine Food Government 119

pharmaphorum

NOVEMBER 2, 2022

The most common solutions today for pain relief are non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, meaning that standard treatments have not changed for a number of years. RelieVRx became the first FDA-authorised treatment for pain delivered at the patient’s home through virtual reality (VR) in November 2021.

Food and Drug Administration 135

Food and Drug Administration Food Patients FDA 135

Pharmaceutical Technology

APRIL 27, 2023

Seres Therapeutics and Nestlé Health Science have received approval from the US Food and Drug Administration (FDA) for Vowst (faecal microbiota spores, live-brpk) for preventing the recurrence of C difficile infection (CDI) in adults. It is not indicated to treat CDI.

Food and Drug Administration 98

Food and Drug Administration FDA Food Patients 98

European Pharmaceutical Review

NOVEMBER 23, 2022

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec), the first gene therapy for adults with Haemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes.

FDA 128

FDA Food and Drug Administration Biopharma Food 128

European Pharmaceutical Review

DECEMBER 7, 2022

In October 2021, The EMA concluded that a booster dose of the Comirnaty ® COVID-19 vaccine can be given to people with severely weakened immune systems, at least 28 days after their second dose. Additional authorisations and recommendations of Comirnaty ®.

Food and Drug Administration 98

Food and Drug Administration Patients Side effects Medicine 98

European Pharmaceutical Review

OCTOBER 31, 2022

Additionally, Danish biotech Genmab has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for epcoritamab for adult patients with R/R large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. ” Clinical trials for epcoritamab, a bsAb drug.

Food and Drug Administration 98

Food and Drug Administration Medicine Food Patients 98

Clarivate

AUGUST 2, 2022

Increased collaboration between regulatory agencies also appears to be having a positive impact on the roll out of new drugs. The following blog post summarizes key findings from the latest CIRS R&D Briefing, New drug approvals in six major authorities 2012-2021. NAS approval times have improved but still differ.

Medicine 98

Medicine Food and Drug Administration FDA Healthcare 98

European Pharmaceutical Review

JULY 28, 2023

The SKYLARK findings support the potential for US Food and Drug Administration (FDA) approval of the first oral, at-home, neuroactive steroid therapy to treat postpartum depression. About the SKYLARK trial There were 200 patients in the SKYLARK study, with 196 female patients between ages 18 to 45 who received the drug.

Food and Drug Administration 98

Food and Drug Administration Food Safety Patients 98

European Pharmaceutical Review

OCTOBER 25, 2022

Phase III trial results found that three years post-treatment, 31 percent of patients given the drug combination were still alive. The US Food and Drug Administration’s (FDA) approval took data from the HIMALAYA Phase III trial into consideration. The statistic for those just offered sorafenib was 20 percent.

Food and Drug Administration 111

Food and Drug Administration Patients Safety Physicians 111

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Medicine 116

Medicine Food and Drug Administration Transportation Distribution 116

European Pharmaceutical Review

MARCH 11, 2024

Employing MALDI-TOF MS for microbial identification in sterile drug manufacturing Fungal contamination in pharmaceutical cleaning facilities Case study examples Mould and yeast have been reported by several previous authors in numerous pharmaceutical cleanrooms , cold rooms, and controlled areas, according to the authors. Ahmed et al.

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Manufacturing Pharmaceutical products 98

European Pharmaceutical Review

DECEMBER 23, 2022

Zynlonta is a CD19-directed antibody drug conjugate (ADC). In April 2021, the US Food and Drug Administration (FDA) granted accelerated approval for Zynlonta as a single-agent treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.

Food and Drug Administration 98

Food and Drug Administration Medicine Medical Food 98

European Pharmaceutical Review

JANUARY 25, 2023

Earlier results from these ongoing trials were published in The New England Journal of Medicine in January 2021 and presented at the European Hematology Association Congress in June 2022.

Medicine 111

Medicine Food and Drug Administration FDA Pharmaceutical 111

European Pharmaceutical Review

FEBRUARY 2, 2024

ADUHELM was the “groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the [Alzheimer’s] field,” commented Christopher Viehbacher, President and Chief Executive Officer of Biogen. ADUHELM received accelerated approval from the US FDA in June 2021, Biogen confirmed.

Food and Drug Administration 97

Food and Drug Administration FDA Food Marketing 97

Pharmaceutical Technology

APRIL 11, 2023

The US Food and Drug Administration (FDA) has granted final approval to India-based Zydus Lifesciences ‘ 500mg azithromycin tablets for the treatment of bacterial infections. Zydus will manufacture the drug at its formulation facility in Moraiya, Ahmedabad, in the Indian state of Gujarat.

Food and Drug Administration 52

Food and Drug Administration FDA Manufacturing Government 52

Pharmaceutical Technology

MARCH 30, 2023

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research and the Lupus Accelerating Breakthroughs Consortium (Lupus ABC) have launched the Lupus Research Alliance (LRA) in a bid to advance research for the condition. Asian, Hispanic, and Native American women are also at higher risk.

Food and Drug Administration 64

Food and Drug Administration FDA Government Food 64

European Pharmaceutical Review

AUGUST 16, 2022

In January 2021, BeiGene and Novartis announced a collaboration granting Novartis rights to co-develop, manufacture, and commercialise BeiGene’s tislelizumab in North America, Europe, and Japan. Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimise binding to Fc-gamma (Fc?)

Food and Drug Administration 98

Food and Drug Administration Patients Safety Food 98

European Pharmaceutical Review

JUNE 29, 2023

Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. 1 Nitrosamines are not new or unknown impurities.

Food and Drug Administration 98

Food and Drug Administration Manufacturing Food Medicine 98

Pharmaceutical Technology

NOVEMBER 29, 2023

BrainStorm Cell Therapeutics’s NurOwn is approaching the conclusion of a three-year regulatory journey that commenced in February 2021 when the US Food and Drug Administration (FDA) advised against filing a Biologics License Application (BLA).

Food and Drug Administration 52

Food and Drug Administration FDA Food 52

European Pharmaceutical Review

SEPTEMBER 29, 2022

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

Management 97

Management Food and Drug Administration Manufacturing Pharmaceutical manufacturing 97

Pharmaceutical Technology

JULY 20, 2022

On 6 July, in an effort to accelerate access, the US Food and Drug Administration (FDA) allowed pharmacists to also begin prescribing the drug to eligible individuals with Covid-19. The pharmacist can then review their medical history to make sure there are no concerns of drug-drug interactions with Paxlovid.

Food and Drug Administration 111

Food and Drug Administration Physicians Medical Prescription 111

European Pharmaceutical Review

NOVEMBER 4, 2022

Nevertheless, chemotherapy’s disadvantages, including substantial toxicities, combined with inconvenient hospital-based intravenous (IV) administration, impede patients’ ability to stay on treatment and their quality of life. tumour effects. The importance of taxanes in oncology.

Food and Drug Administration 98

Food and Drug Administration Pharmaceutical FDA Patients 98

European Pharmaceutical Review

FEBRUARY 6, 2025

The US Food and Drug Administration (FDA) has approved Genentechs Susvimo (ranibizumab injection) 100 mg/mL as the first treatment for diabetic macular oedema (DME) via continuous delivery. The FDA first authorised Susvimo for wet, or neovascular age-related macular degeneration (AMD) in 2021, Genentech shared.

Food and Drug Administration 52

Food and Drug Administration FDA Medical Food 52

Pharmaceutical Technology

MAY 24, 2023

Inovio has received orphan drug designation for INO-3107 from the European Commission (EC) to treat recurrent respiratory papillomatosis (RRP). In July 2020, the US Food and Drug Administration (FDA) also granted orphan drug designation to INO-3107.

Food and Drug Administration 52

Food and Drug Administration Medicine Food Marketing 52

European Pharmaceutical Review

NOVEMBER 22, 2022

The US Food and Drug Administration ( FDA ) has accepted priority review of AbbVie’s Biologics License Application of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody (BsAb), for adults with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

FDA 98

FDA Food and Drug Administration Safety Food 98

European Pharmaceutical Review

MARCH 4, 2024

1 However, the entry of biologics into the pharmaceutical market is not without unique challenges, particularly when compared to small molecule drugs. Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5

Food and Drug Administration 98

Food and Drug Administration Transportation FDA Medical 98

European Pharmaceutical Review

MARCH 13, 2024

FDA inspections Identification of data integrity deviations Of the 70 Warning Letters issued by the US Food and Drug Administration (FDA) so far in 2024, three have identified data integrity issues at pharmaceutical manufacturing sites outside the US. In a letter issued to China-based Sichuan Deebio Pharmaceutical Co.

FDA 98

FDA Food and Drug Administration Manufacturing Pharmaceutical manufacturing 98

European Pharmaceutical Review

OCTOBER 10, 2022

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline Biologicals’ Boostrix vaccine for use in pregnant woman in their third trimester, to prevent against whooping cough (pertussis) in infants up to two months of age. percent of whooping cough cases in 2021 were those six months or younger.

FDA 105

FDA Food and Drug Administration Side effects Food 105

European Pharmaceutical Review

OCTOBER 25, 2023

The document by the Medicines and Healthcare products Regulatory Agency (MHRA), US Food and Drug Administration (FDA) and Health Canada, contains key guidance on predetermined change control plans (PCCPs) for MLMDs.

Medical 105

Medical Food and Drug Administration Manufacturing Safety 105

European Pharmaceutical Review

AUGUST 11, 2022

The study compared outcomes for 110 patients treated with remdesivir and dexamethasone and 81 treated with both those medications plus baricitinib at Saint Peter’s University Hospital in New Jersey, USA, between June 2020 and June 2021. .

Food and Drug Administration 96

Food and Drug Administration Patients Medical Food 96

European Pharmaceutical Review

SEPTEMBER 2, 2022

An RMP is submitted as part of the dossier of all new drug applications and is evaluated by regulatory authorities before authorisation is given. Jouaville: Most RMM effectiveness studies are formatted as surveys or drug utilisation studies (DUS). US Food and Drug Administration. Available from: [link].

Food and Drug Administration 96

Food and Drug Administration Medicine Safety Food 96

European Pharmaceutical Review

AUGUST 10, 2022

It was approved by the US Food and Drug Administration in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA-associated vasculitis), in combination with standard therapy.

Food and Drug Administration 97

Food and Drug Administration Pharmaceutical Food Medical 97